N | n | Univariate analysis | Adjusted analysis | |||||
---|---|---|---|---|---|---|---|---|
IRR | (95 % IC) | p-value | aIRR | (95 % CI) | p-value | |||
Antiretroviral therapy (ART) and cotrimoxazole exposure | <0.01 | <0.01 | ||||||
On ART - On cotrimoxazole | 667 | 7 | 0.07 | (0.02-0.21) | <0.01 | 0.05 | (0.02-0.18) | <0.01 |
Off ART - On cotrimoxazole | 83 | 2 | 0.16 | (0.03-0.80) | 0.03 | 0.13 | (0.02-0.69) | 0.02 |
On ART - Off cotrimoxazole | 332 | 34 | 0.69 | (0.27-1.77) | 0.44 | 0.69 | (0.27-1.77) | 0.44 |
Off ART - Off cotrimoxazole | 35 | 5 | 1 | - | - | 1 | - | - |
Immunodeficiency for Age a | 0.38 | 0.02 | ||||||
Severe | 69 | 5 | 1.87 | (0.73-4.76) | 0.19 | 4.03 | (1.55-10.47) | <0.01 |
Moderate | 106 | 6 | 1.44 | (0.61-3.40) | 0.41 | 2.14 | (0.89-5.14) | 0.09 |
No/Missing | 942 | 40 | 1 | - | - | 1 | - | - |
Age | 0.14 | |||||||
<5 years | 144 | 11 | 2.18 | (1.04-4.58) | 0.04 | Not included | ||
[5-10[years | 443 | 18 | 1.13 | (0.59-2.16) | 0.70 | |||
≥10 years | 530 | 19 | 1 | - | - | |||
Centres | <0.01 | |||||||
CHU de Cocody | 182 | 1 | 1 | - | - | |||
CHU de Yopougon | 344 | 9 | 4.80 | (0.61-37.87) | 0.14 | Not included | ||
CePReF | 322 | 20 | 11.66 | (1.56-86.91) | 0.02 | |||
CIRBA | 212 | 7 | 6.11 | (0.75-49.65) | 0.09 | |||
MTCT-Plus | 57 | 11 | 38.72 | (5.00-299.97) | <0.01 |